Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Abbott To Present Phase2 Result From InterferonFree Studies For Treatment Of HCV

Abbott Laboratories (ABT: Quote) said that it will present clinical trial results from two different interferon-free, Phase 2 studies for the treatment of hepatitis C or HCV at the International Liver Congress 2012 or ILC 2012, the annual meeting of the European Association for the Study of the Liver or EASL, April 18-22 in Barcelona, Spain.

In the study known as "Co-Pilot," different doses of ABT-450/r, plus ABT-333 and ribavirin administered for 12 weeks showed sustained virological response at 12 weeks post treatment or SVR12 in 95 percent and 93 percent of treatment-naive genotype 1 or GT1 patients.

In these patients, response was independent of HCV subtype, host IL28B genotype or dose of ABT-450/r. In addition, SVR12 was achieved in 47 percent of patients who were previous non-responders to past HCV treatment, the company said.

In a separate study, known as "Pilot," 91 percent of genotype 1 infected, treatment-naive patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks, achieved sustained viral response at 24 weeks or SVR24, Abbott noted.

Click here to receive FREE breaking news email alerts for Abbott Laboratories and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Denis Mukwege, a doctor from the Democratic Republic of Congo, has won this year's Sakharov Prize for Freedom of Thought for helping thousands of gang rape victims in the country. The award was instituted by the European Parliament, and the laureate for 2014 was selected by EP President Martin Schulz and the political group leaders. Announcing Europe's top human rights prize Tuesday, Schulz said Stocks moved sharply higher over the course of the trading day on Tuesday, extending the recovery from the sell-off seen in recent weeks. The Nasdaq and the S&P 500 closed higher for the fourth consecutive session but remain well off their mid-September highs. Despite indications that the spread of Ebola inside the U.S. has been contained, the results of a new Gallup poll show the deadly disease had made its debut on a list of the top 10 most important problems facing the country.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.